Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Clin Lipidol ; 13(4): 645-653.e2, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31126864

RESUMEN

BACKGROUND: Previous studies indicate that circadian preference is associated with various energy metabolism and metabolic disorders. However, little is known about the associations between a circadian rhythm and blood lipid levels, especially in humans. OBJECTIVE: The aim of the study was to investigate whether the circadian rhythm affects serum lipid levels in Korean adults. METHODS: We designed a cross-sectional study to evaluate the associations between circadian preference and blood lipid levels in Korean adults. A total of 1984 participants (range of age 19-81 years) were included in this study. Propensity scores were calculated using logistic regression with age, sex, and body mass index. A total of 435 subjects were evaluated by propensity score matching analysis, equally distributed into morningness, intermediate, and eveningness groups, each with 145 subjects. Circadian preference was evaluated by the Morningness-Eveningness Questionnaire. RESULTS: Participants with the evening preference had significantly higher levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol (non-HDL-C) when compared with those with morning or intermediate preference, after adjusting for confounding variables. Regarding other lipid parameters, both total cholesterol/HDL-C and low-density lipoprotein cholesterol/HDL-C in the evening preference are significantly higher than those of other circadian preferences. Evening preference was also significantly associated with a higher atherogenic index of plasma. CONCLUSION: Our study demonstrates that there is a significant association between circadian preference and blood lipid levels. Our findings suggest that individuals with evening preference could have a greater risk of atherosclerotic cardiovascular diseases.


Asunto(s)
Ritmo Circadiano/fisiología , Lípidos/sangre , Adulto , Anciano , Índice de Masa Corporal , Estudios Transversales , Femenino , Humanos , Lipoproteínas/sangre , Modelos Logísticos , Masculino , Persona de Mediana Edad , Puntaje de Propensión , Estudios Retrospectivos , Trastornos del Sueño-Vigilia/patología , Encuestas y Cuestionarios , Adulto Joven
2.
J Endocrinol Invest ; 38(1): 65-71, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25053396

RESUMEN

BACKGROUND: Mercury exposure enhances free radical production and reduces activity of anti-oxidant enzymes, resulting in detrimental health effects. Some researchers have reported an association between blood mercury and increased risk of metabolic syndrome (MetS); however, sex differences in the relationship were not fully considered. AIM: To examine the sex differences in the relationship between blood mercury concentration and the increased risk of MetS in Korean men and women. MATERIALS AND METHODS: A nationwide cross-sectional study was conducted to examine the relationship between blood mercury concentration and MetS in 2,976 men and 3,074 women over 19 years of age (aged 19-87 years), using data from the 2010-2012 Korean National Health and Nutrition Examination Survey (KNHANES-V). Multiple logistic regression analysis was used to assess the relationship between blood mercury concentration and the prevalence risk of MetS after adjusting for confounding variables. RESULTS: Compared to the lowest quartile of blood mercury concentration, the OR (95 % CI) for MetS of the highest quartile in men was 1.62 (1.15-2.28) after adjusting for age, smoking status, alcohol consumption, regular exercise, and BMI. Similarly, in multiple logistic regression analysis using log2-transformed blood mercury as a continuous variable, the OR (95 % CI) for having MetS with doubling of blood mercury was 1.20 (1.05-1.36) after adjusting for the same co-variables. However, the relationship was not observed in women after adjusting for the same co-variables. CONCLUSIONS: Blood mercury concentration was independently associated with an increased risk of MetS in men.


Asunto(s)
Mercurio/sangre , Síndrome Metabólico/sangre , Síndrome Metabólico/diagnóstico , Caracteres Sexuales , Adulto , Biomarcadores/sangre , Estudios Transversales , Femenino , Humanos , Masculino , Síndrome Metabólico/epidemiología , Persona de Mediana Edad , Encuestas Nutricionales/métodos , República de Corea/epidemiología , Factores de Riesgo
3.
Nutr Res Pract ; 7(6): 495-502, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24353836

RESUMEN

Recent studies suggest that vitamin D deficiency and cardiometabolic disorders are becoming increasingly more prevalent across multiple populations. However, there is a lack of comprehensive data for Korean adults. We investigated the vitamin D status, the prevalence of vitamin D deficiency and its association with metabolic syndrome (MS) risk in Korean adults aged 20 years or older. The study subjects (n = 18,305) were individuals who participated in the Korean National Health Examination and Nutrition Survey (KNHANES) in 2008-2010. Vitamin D status (25-hydroxyvitamin D [25(OH)D]) was categorized as < 20, 21-29, and ≥ 30 ng/mL, which are the cut-off points for deficiency, insufficiency and normal limits. A wide variety of cardiometabolic risk factors were compared according to the vitamin D status. Vitamin D deficiency was found in 53.9% of men and 70.5% of women. Mean BMI, systolic BP, HbA1c and low density lipoprotein cholesterol (LDL-C) were highest in the vitamin D deficiency group in both genders. Further, the MS was most prevalent in the vitamin D deficiency group in both genders (12.3%, P = 0.002 in men and 9.2%, P < 0.001 in women). Compared to the vitamin D normal group, the adjusted odds ratio (ORs) (95% confidence interval [95% CI]) for MS in the vitamin D deficiency group were 1.46 (1.05-2.02) in men and 1.60 (1.21-2.11) in women, after adjusting for confounding variables. In conclusion, Vitamin D deficiency is a very common health problem in Korean adults and is independently associated with the increasing risk of MS.

4.
J Pediatr Endocrinol Metab ; 26(1-2): 105-10, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23329742

RESUMEN

BACKGROUND: Although the metabolic syndrome (MetS) in childhood is increasing worldwide and becoming a significant public health problem, some countries report trends for stabilization. After 2005, the Health Plan 2010 of the Korean Ministry of Health and Welfare has carried out the standardization of school lunch provisions for all students and reinforced nutritional and physical education in schools. Thus, an investigation of changes in the prevalence of MetS in Korean children and adolescents is important and intriguing in the aspect of evaluating the national public health intervention. METHODS: We investigated trends in the prevalence of MetS among a nationally representative sample of 5652 children and adolescents aged 10-18 years from the Korean National Health and Nutrition Examination Surveys (KNHANES) I (1998), II (2001), III (2005), and IV (2008). RESULTS: Prevalence trends in MetS were 7.5%, 9.8%, 10.9%, and 6.7% in the KNHANES I through IV, respectively (p<0.001). Among the five components of MetS, the prevalence of low high-density lipoprotein (HDL) cholesterol increased most over the 1998-2005 period and decreased over the 2005-2008 period. CONCLUSION: The prevalence of MetS has decreased since 2005 mainly because of changes in the prevalence of low levels of HDL cholesterol.


Asunto(s)
Síndrome Metabólico/epidemiología , Adolescente , Edad de Inicio , Presión Sanguínea/fisiología , Niño , HDL-Colesterol/sangre , Estudios Transversales , Femenino , Humanos , Masculino , Síndrome Metabólico/sangre , Síndrome Metabólico/fisiopatología , Actividad Motora/fisiología , Encuestas Nutricionales/estadística & datos numéricos , Encuestas Nutricionales/tendencias , Prevalencia , República de Corea/epidemiología
5.
Arch Gerontol Geriatr ; 56(1): 270-8, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23079031

RESUMEN

Important changes in body composition with aging are a progressive loss of muscle mass and increase of fat mass. Despite their enormous clinical importance, body composition changes such as sarcopenic obesity in the elderly are under-recognized. This study aimed to examine the relationship of body composition with a wide variety of cardiometabolic risk factors among 2943 subjects (1250 men and 1693 women) aged 60 years or older from Korean National Health Examination and Nutrition Survey (KNHANES). Sarcopenia was defined as an appendicular skeletal muscle mass (ASM) divided by weight (%) of < 1 SD below the sex-specific mean for young adults. Obesity was defined as a body mass index (BMI) ≥ 25 kg/m(2). Body composition was categorized into four non-overlapping groups: the sarcopenic obese, sarcopenic nonobese, nonsarcopenic obese, and nonsarcopenic nonobese groups. A wide variety of cardiometabolic risk factors, including blood pressure (BP), glucose tolerance indices, lipid profiles, inflammatory markers, and vitamin D level, were compared according to body composition group. The prevalence of sarcopenic obesity was 18.4% in men and 25.8% in women. In both sexes, the prevalence of vitamin D deficiency and metabolic syndrome was highly prevalent in the sarcopenic obese group. Serum insulin level, homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride levels, and ferritin levels were the highest in the sarcopenic obese group in both men and women, whereas HDL-cholesterol and 25-hydroxyvitamin D (25(OH)D) levels were the lowest in the sarcopenic obese group. The sarcopenic obese group was more closely associated with insulin resistance, metabolic syndrome, and cardiovascular disease (CVD) risk factors than any other group in this elderly population.


Asunto(s)
Composición Corporal , Enfermedades Cardiovasculares/etiología , Obesidad/complicaciones , Sarcopenia/complicaciones , Anciano , Análisis de Varianza , Composición Corporal/fisiología , Índice de Masa Corporal , Distribución de Chi-Cuadrado , Estudios Transversales , Femenino , Humanos , Resistencia a la Insulina/fisiología , Masculino , Síndrome Metabólico/etiología , Persona de Mediana Edad , Factores de Riesgo , Estadísticas no Paramétricas , Deficiencia de Vitamina D/complicaciones
6.
J Korean Med Sci ; 24(5): 874-8, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19794986

RESUMEN

Although cabergoline is effective in the treatment of micro- and macro-prolactinoma, little is known about its efficacy in the treatment of invasive giant prolactinoma. We investigated the efficacy and safety of cabergoline in 10 male patients with invasive giant prolactinoma. Before treatment, mean serum prolactin level was 11,426 ng/mL (range, 1,450-33,200 ng/mL) and mean maximum tumor diameter was 51 mm (range, 40-77 mm). Three months after initiation of cabergoline treatment, serum prolactin concentrations decreased more than 97% in 9 patients; at last follow-up (mean treatment duration, 19 months), the mean decrease in serum prolactin concentrations was 98%, with 5 patients having normal serum prolactin levels. At first MRI follow-up (3-12 months after initiation of cabergoline), the mean reduction in tumor size was 85+/-4% (range, 57-98%). Cabergoline treatment for more than 12 months caused a greater reduction in tumor size compared to the treatment for less than 12 months (97+/-1% vs. 78+/-7%, P<0.05). These findings indicate that cabergoline treatment led to a significant and rapid reduction in serum prolactin concentrations and tumor size in patients with giant prolactinoma. Therefore, cabergoline represents an effective and well-tolerated treatment for invasive giant prolactinoma.


Asunto(s)
Antineoplásicos/uso terapéutico , Ergolinas/uso terapéutico , Neoplasias Hipofisarias/tratamiento farmacológico , Prolactinoma/tratamiento farmacológico , Adulto , Antineoplásicos/efectos adversos , Cabergolina , Ergolinas/efectos adversos , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Prolactina/sangre , Estudios Retrospectivos
7.
Am J Obstet Gynecol ; 189(1): 261-6, 2003 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-12861172

RESUMEN

OBJECTIVE: Cyclo-oxygenase inhibitors have different selectivity for inhibitory action on the isoforms of the enzyme. Our purpose was to compare the tocolytic and maternal toxic effects of various cyclo-oxygenase inhibitors in the lipopolysaccharide-induced preterm birth in pregnant mice. STUDY DESIGN: We randomly assigned 50 ICR pregnant mice into five groups of 10 mice each and treated them intraperitoneally with either phosphate-buffered saline solution or lipopolysaccharide (50 microg) on day 15 of pregnancy. Of the four groups that received lipopolysaccharide, three groups also were treated either with nonselective cyclo-oxygenase inhibitors (indomethacin [1 mg/kg/d] or diclofenac [2 mg/kg/d]) or with the cyclo-oxygenase-2 preferential inhibitor, meloxicam (2 mg/kg/d), with a gavage tube on days 15 through 18 of pregnancy or until maternal death. The mice were killed immediately after preterm birth or on day 21 of pregnancy. Preterm birth rates and maternal side effect profiles were evaluated. RESULTS: Preterm birth occurred in 90% of mice after intraperitoneal lipopolysaccharide injection and in 20% of mice after phosphate-buffered saline solution injection. Indomethacin and meloxicam, but not diclofenac, significantly decreased the incidence of preterm birth that was induced by lipopolysaccharide (33.3% and 33.3%, respectively; P =.028). Although the overall incidence of maternal gastric and/or renal toxicities was not significantly increased in the indomethacin or meloxicam groups, a significant increase was noticed in the diclofenac group compared with the lipopolysaccharide-treated control group (P =.006). CONCLUSION: Indomethacin and meloxicam, but not diclofenac, inhibit the lipopolysaccharide-induced preterm birth in an animal model. Meloxicam appears to have no advantage over indomethacin with regard to tocolysis and maternal side effects.


Asunto(s)
Inhibidores de la Ciclooxigenasa/uso terapéutico , Lipopolisacáridos , Trabajo de Parto Prematuro/prevención & control , Animales , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Diclofenaco/efectos adversos , Diclofenaco/uso terapéutico , Femenino , Indometacina/efectos adversos , Indometacina/uso terapéutico , Isoenzimas/antagonistas & inhibidores , Enfermedades Renales/inducido químicamente , Meloxicam , Ratones , Ratones Endogámicos ICR , Trabajo de Parto Prematuro/inducido químicamente , Embarazo , Resultado del Embarazo , Prostaglandina-Endoperóxido Sintasas , Gastropatías/inducido químicamente , Tiazinas/efectos adversos , Tiazinas/uso terapéutico , Tiazoles/efectos adversos , Tiazoles/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA